The Effects of Secondary Pneumonia on the Curative Efficacy of Multidrug-resistant Tuberculosis: A Retrospective Cohort Study

Tuberculosis (TB) is a formidable global health problem and ranks above HIV as the leading cause of death worldwide. In 2017, a total number of 10.0 million cases of TB were reported, which resulted in 1.3 million TB deaths. Resistance to standard anti-TB drugs poses a major threat to control of TB, and 450, 000 cases of multidrug-resistant TB (MDR-TB) were estimated in 2017, which indicates the severity of the problem^[1]. Pneumonia is one of the common infectious diseases that cause morbidity and mortality in China, causing approximately 2.5 million new cases and 125, 000 deaths annually^[2]. Particularly, a high risk of pneumonia in TB was observed among patients with TB compared to that in the general population^[3]. Regarding patients with MDR-TB, the extensive for the focus of lung^[4] and lung dysbacteriosis^[5] further increase the risk of secondary pneumonia, and the role of secondary pneumonia in the efficacy of anti-TB treatment needs to be delineated.

Therefore, we investigated the association between secondary pneumonia and the outcome of MDR-TB treatment. Patients newly diagnosed as MDR who were retrospectively treated over a period of 12 months in Guangzhou Chest Hospital Tuberclusis Department between January 2014 and January 2017 were included in this study, and those patients who were transferred out or those whose treatment period was for < 12 months were excluded. Assessment was focused on demographic characteristics, chest radiographs, baseline information about comorbidities, serum albumin level, absolute lymphocyte count, sputum analysis results, and certain follow-up information during and after treatment or censorship (death, default, and study termination). The study was approved by the Guangzhou Chest Hospital Ethics Committee. Since this is a retrospective study, no consent for participation was obtained.

For purposes of this study, pneumonia was diagnosed based on clinical signs and chest X-ray features of pneumonia. In addition, complete blood count and sputum culture were performed to establish the causative agent of the pneumonia. All patients in this study were treated using a regimen of amikacin (AMK) or capreomycin (CAP), levofloxacin (LFX) or moxifloxacin (MFX), protionamide (PTO) or p-aminosalicylate (PAS), cycloserine (CLS) or ethambutol (EMB), and pyrazinamide (PZA) for 6 months or LFX or MFX, PTO or PAS, CLS or EMB, and PZA for 18 months. The outcomes of interest were time to sputum-negative conversion, and the rate of sputum culture conversion depending on the treatment outcome (cured, treatment completed, treatment default, treatment failure, and died) classification was based on the World Health Organization (WHO) guidelines^[6].

Among the 120 patients in this study, 70 developed secondary pneumonia and were categorized into the pneumonia group, and the remaining 50 patients were classified as the control group as they did not develop secondary pneumonia. The incidence density of secondary pneumonia among the patients was 61.8 per 100 person-years. The baseline demographic characteristic results pertaining to drug susceptibility testing, smoking, hypoproteinemia, absolute lymphocyte count, comorbidities, and characteristics changes on chest radiographs are presented in Table 1.

Sputum-negative culture conversion occurred significantly later among the patients with secondary pneumonia (with pneumonia vs. without pneumonia, 512.5 days vs. 263.1 days, P < 0.001), as depicted in Figure 1. In addition, multivariate analysis was performed to adjust for confounders based on unadjusted results, and the association between secondary pneumonia and sputum-negative culture conversion remained uncharged (aHR = 0.354, P = 0.001), as shown in Table 2.

Figure 1.  Time to sputum-negative conversion in these two groups.

Of the 71 patients with MDR-TB who showed WHO-defined treatment outcome, 11 (15.5%) were cured and 8 (11.3%) completed treatment. The others had poor treatment outcomes and included 26 (36.6%) with defaulted treatment and 21 (29.6%) with treatment failure, whereas 5 (7.0%) patients died. After adjusting for multiple confounders, the results showed that secondary pneumonia increased the risk of poor outcome, although the association was not significant (RR = 1.647, P = 0.146) (Table 2).

Our findings suggested that secondary pneumonia is a significant risk factor that prolonged sputum-negative conversion and treatment failure. Advanced lung disease would lead to lung parenchyma damage, which further compromises the bioavailability of drugs to such tissues^{[5, 7]}, resulting in high burden of TB. In this context, the association between cavities and delayed sputum-negative conversion also supported this issue^[8].

In particular, previous studies have demonstrated a significant prognostic role of hypoproteinemia in patients with MDR-TB, which suggests the association between malnutrition and poor treatment outcome^{[8, 9]}. Our results showed that malnutrition increased the risk of pneumonia, whereas pneumonia accounted for the malnutrition, resulting in a vicious cycle of infection and malnutrition.

Table 3 shows the results of progression over consecutive sputum cultures. The rate of sputum-negative conversion was significantly lower in the pneumonia group than that in the control group (37.1% vs. 72.0%, P < 0.001). Most importantly, patients with secondary pneumonia easily reconverted to positive events (26.9% in the pneumonia group vs. 11.1% in the control group). Secondary pneumonia reduced the rate of sputum-negative conversion while at the same time led to positive event reconversion. Furthermore, pneumonia increased the minimum time needed for sputum culture-negative conversion. It is worth noting that the time to sputum-negative conversion is associated with treatment outcome in TB^[6] and, as indicated by Kurbatova^[10], suggests that sputum-negative conversion in 6 months could be a prognostic marker for treatment success. It is therefore not surprising that treatment did not confer similar benefits to patients who converted later during the course of treatment, regardless of the secondary pneumonia or not. All these findings indicate the close association that exists between delayed sputum-negative conversion and poor treatment outcome.

Studies investigating lung morphological changes and treatment outcome have demonstrated that advanced lung disease reduces drug bioavailability, which eventually leads to poor treatment outcome in TB^[5]. Interestingly, our study also revealed an association between chest opacifications and delayed sputum-negative conversion.

No conflict of interest to declare.

We would like to thank the management of Guangzhou Chest Hospital for allowing us to carry out the study.